Immupharma PLC Result of AGM
28 6월 2024 - 8:17PM
RNS Regulatory News
RNS Number : 3931U
Immupharma PLC
28 June 2024
RNS:
RELEASE
28 June 2024
ImmuPharma
PLC
("ImmuPharma" or the "Company")
2024 RESULT OF ANNUAL GENERAL MEETING -
ALL RESOLUTIONS PASSED
ImmuPharma
PLC (LSE:IMM), the specialist drug discovery and development
company, held its AGM earlier today. The Company is
pleased to announce that all resolutions were duly passed, details
of which are contained in the table below.
|
Resolution
|
For
|
% For
|
Against
|
% Against
|
Withheld
|
|
1. To receive the accounts of the Company for the year
ended 31 December 2023 together with the reports thereon of the
directors and auditors of the Company
|
86,062,471
|
100%
|
2,400
|
0.00%
|
11,950
|
|
2. To re-appoint Dr Laurence Reilly as a
director of the Company
|
80,641,856
|
97.22%
|
2,305,727
|
2.78%
|
3,129,241
|
|
3. To re-appoint Dr Sebastian Goudreau as a
director of the Company
|
82,355,053
|
97.28%
|
2,305,727
|
2.72%
|
1,416,044
|
|
4. To re-appoint Lisa Baderoon as a director of
the Company
|
82,357,053
|
97.28%
|
2,305,727
|
2.72%
|
1,414,044
|
|
5. To re-appoint CLA Evelyn Partners Limited as Auditor
of the Company
|
81,844,124
|
97.25%
|
2,318,324
|
2.75%
|
1,914,376
|
|
6. That the Directors be authorised for the
purpose of Section 551 of the Companies Act 2006 (the "Act") to
allot shares on the basis as set out in the Notice of
Meeting
|
81,127,174
|
95.26%
|
4,040,309
|
4.74%
|
909,338
|
|
SPECIAL RESOLUTION
7. That, subject to
the passing of Resolution 6 the directors be and they are hereby
empowered pursuant to section 571 of the Act to allot equity
securities as set out in the Notice of Meeting
|
81,127,174
|
95.26%
|
4,040,309
|
4.74%
|
909,338
|
As at the date of the AGM, the number of issued
ordinary shares of the Company was 416,437,265 shares, which was the total
number of shares entitling the holders to attend and vote for or
against all resolutions. In accordance with the Company's Articles
of Association, every member has one vote for every share
held. Votes withheld are not votes in law and have not been
counted in the calculation of the proportion of vote "for" or
"against" a resolution. Proxy appointments which gave
discretion to the Chairman have been included in the "for"
total.
This announcement contains
inside information as stipulated under the UK version of the Market
Abuse Regulation no 596/2014 which is part of English law by virtue
of the European (withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
Ends
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chief Executive
Officer and Chairman
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 203 650 3650/51
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140 is a first-in class autophagy
immunomodulator for the treatment of Lupus and CIDP and preclinical
analysis suggests P140 may have therapeutic benefit in many other
autoimmune diseases that are caused by the same dysfunction in the
immune system.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGMZGZVMRFGDZM
Immupharma (LSE:IMM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Immupharma (LSE:IMM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
